Abstracts tagged "T cells and takayasu arteritis"

Abstract Number: 2731 • 2014 ACR/ARHP Annual Meeting
Th1 and Th17 Cytokines Drive Takayasu Arteritis Inflammation
David Saadoun¹, Marlène Garrido², Cloé Comarmond³, Anne-Claire Desbois⁴, Fanny Domont⁴, Léa Savey⁵, Benjamin Terrier⁶, Michelle Rosenzwajg⁷, David Klatzman⁸, Pierre Fourret⁹, Philippe Cluzel¹⁰, Laurent Chiche¹¹, Julien Gaudric¹², Fabien Koskas¹³ and Patrice Cacoub¹⁴, ¹DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Internal medicine and clinical immunology, UMR 7211, INSERM U959, Hôpital Pitié-Salpêtrière, Paris, France, ³Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, ⁴Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ⁵Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, P, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁷UMR 7211, INSERM U959, Hôpital Pitié-Salpêtrière, Paris, France, ⁸UPMC Université Paris 06, UMR 7211, Paris, France, ⁹Hôpital Pitié-Salpêtrière, Anathomopathology, Paris, France, ¹⁰Vascular and Interventional Imaging Department, Paris, France, ¹¹Vascular Surgery, Paris, France, ¹²Department of Vascular surgery GHPS, Paris, France, ¹³Vascular Surgery, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ¹⁴Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France
Background/Purpose: Takayasu arteritis (TA) is a large-vessel vasculitis inducing damage of the aorta and its branches. Glucocorticoids remain the gold standard of therapy in TA.…
Abstract Number: 806 • 2014 ACR/ARHP Annual Meeting
Association of a Single Nucleotide Polymorphism (SNP) in IL-12B Region with Clinical Features and Peripheral T Cell Profiles of Patients with Takayasu Arteritis
Toshiki Nakajima¹, Hajime Yoshifuji¹, Chikashi Terao², Koji Kitagori¹, Ran Nakashima¹, Yoshitaka Imura³, Naoichiro Yukawa¹, Koichiro Ohmura¹, Takao Fujii¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose We preliminarily found a SNP (A vs. C, rs6871626)　in IL-12B region　as a susceptibility gene to Takayasu arteritis (TAK) by genome-wide association study. IL-12Bencodes IL-12/IL-23…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].